WIXOM, Mich., Dec. 10, 2018 /PRNewswire/ -- Rockwell Medical,
Inc. (NASDAQ: RMTI) (the "Company" or "Rockwell Medical") today
announced that Michael DeYoung has
been appointed Vice President, Operations, effective immediately.
Mr. DeYoung will report to Stuart
Paul, President and Chief Executive Officer of the Company.
As Vice President, Operations, Mr. DeYoung will be responsible for
leading Rockwell Medical's newly formed Operations Team, in
addition to overseeing manufacturing operations, logistics and
company-wide strategy deployment. Within these areas, Mr. DeYoung
will oversee key initiatives that support the launch of Triferic®
in the U.S. and globally.
Mr. DeYoung joins Rockwell Medical from ZDHF Holdings, LLC, a
storage and logistics firm, where he served as Chief Financial
Officer. Previously, he held the role of Group Director of the Moog
Medical Device Group of Moog Inc., where he was responsible for
finance, human resources and IT operations and played a key role in
the turnaround of the division. From 2008 to 2013, Mr. DeYoung
worked at Gambro AB, a global medical technology and pharmaceutical
company and leader in dialysis products, where he led operational
initiatives contributing to the successful exit and sale of the
company to Baxter International. Following the sale of Gambro AB to
Baxter in 2013, Mr. DeYoung served as Director of Integration and
Business Operations and was responsible for the full integration of
the Baxter and Gambro renal operations in Latin America. He spent the early part of his
career at IMI Norgren, a world leader in motion and fluid control
technologies, where he held various roles in manufacturing, project
management, finance and business controls. Mr. DeYoung holds a
Bachelor's Degree in Business Management, General Business from
Western Michigan University and a
Master's Degree in Accounting from Walsh
College.
Mr. Paul stated, "Mike's breadth of experience in operational
leadership and strategic program management make him ideally suited
to contribute to Rockwell Medical as we work to position our
resources most efficiently and execute against our goals, including
our planned commercial launch of Dialysate Triferic in the U.S. in
the first half of 2019. Mike has a proven track record of driving
value and delivering results, and I am confident that he has the
expertise necessary to oversee and improve operations."
Mr. Paul continued, "One of my priorities since joining Rockwell
Medical was to further build-out the senior management team and I
am pleased to announce that with Mike on board, we've now completed
the hiring of all critical senior leadership positions. Together,
these individuals bring essential business experience, as well as
expertise in the renal therapy and specialty pharmaceutical space.
I am enthusiastic about the talented team we have assembled."
"I am excited to join Rockwell Medical and to be working
alongside the team to best position our valuable assets," said Mr.
DeYoung. "I look forward to applying my experience and operational
know-how as we focus on achieving our key milestones."
Mr. Paul's appointment as President and CEO of Rockwell Medical
became effective on September 4,
2018. Since that time, Mr. Paul has appointed the following
individuals to the Rockwell Medical senior leadership team:
- Angus Smith, Chief Financial
Officer;
- Jim McCarthy, Senior Vice
President, Corporate Business Development;
- Charlie Shiner, Vice President,
Marketing;
- Michael DeYoung, Vice President,
Operations; and
- Anne Boardman, Vice President,
Sales and Strategic Accounts.
About Rockwell Medical, Inc.
Rockwell Medical is a biopharmaceutical company targeting
end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Rockwell Medical's exclusive renal drug therapies support disease
management initiatives to improve the quality of life and care of
dialysis patients and are intended to deliver safe and effective
therapy, while decreasing drug administration costs and improving
patient convenience. Rockwell Medical's anemia drug Triferic is the
only FDA-approved product indicated for iron replacement and
maintenance of hemoglobin in hemodialysis patients. Rockwell's FDA
approved generic drug Calcitriol (active vitamin D) is for treating
secondary hyperparathyroidism in patients undergoing chronic renal
dialysis. Rockwell Medical is also an established manufacturer,
supplier and leader in delivering high-quality hemodialysis
concentrates/dialysates (used to maintain human life by removing
toxins and replacing critical nutrients in the dialysis patient's
bloodstream) to dialysis providers and distributors in the U.S. and
abroad. Please visit www.rockwellmed.com for more information.
Forward-Looking Statement
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws, including, but not limited to, Rockwell's
intention to bring to market Triferic, IV Triferic and Calcitriol.
Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "could," "plan,"
"potential," "predict," "forecast," "project," "plan", "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. While
Rockwell believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties (including, without limitation, those set
forth in Rockwell's SEC filings), many of which are beyond our
control and subject to change. Actual results could be materially
different. Risks and uncertainties include: statements about the
timing and success of our planned NDA submission for IV Triferic;
the potential market opportunity for IV Triferic and other Rockwell
products; pricing and reimbursement status for IV Triferic,
Triferic and other Rockwell products, including eligibility for
add-on reimbursement under TDAPA; liquidity and capital resources;
expected duration of Rockwell Medical's existing working capital;
plans and timing relating to the planned commercialization of
Triferic; and timing and success of our efforts to renegotiate
economic terms of our concentrate business Rockwell expressly
disclaims any obligation to update or alter any statements whether
as a result of new information, future events or otherwise, except
as required by law.
Contacts
Dan Katcher / Kelly Sullivan / Arielle
Rothstein
Joele Frank, Wilkinson Brimmer
Katcher
212-355-4449
View original
content:http://www.prnewswire.com/news-releases/rockwell-medical-inc-appoints-new-vice-president-operations-300762403.html
SOURCE Rockwell Medical, Inc.